Profit Margin (Annual)

Profit Margin: Net Income as a portion of total sales revenue. Calculated as: Net Income / Total Revenues

Tarsus Pharmaceuticals, Inc. (TARS) had Profit Margin of -778.89% for the most recently reported fiscal year, ending 2023-12-31.

Quarterly Annual

Figures for fiscal year ending 2023-12-31

Income Statement Financials
Revenue	$17.45M
Net Income	$-135.89M
Cost of Goods Sold	$1.59M
Gross Profit	$15.85M
Operating Expenses	$160.60M
Operating Income	$-143.16M
Non-Operating Income/Expense	$7.26M
Pre-Tax Income	$-135.89M
Normalized Pre-Tax Income	$-135.89M
Income after Taxes	$-135.89M
Income from Continuous Operations	$-135.89M
Consolidated Net Income/Loss	$-135.89M
Normalized Income after Taxes	$-135.89M
EBIT	$-143.16M
EBITDA	$-145.06M
Weighted-Average Shares Outstanding (Basic)	29.38M
Weighted-Average Shares Outstanding (Diluted)	29.38M
Earnings per Share (EPS) (Basic)	$-4.62
Earnings per Share (EPS) (Diluted)	$-4.62
Balance Sheet Financials
Current Assets	$256.13M
Property, Plant, and Equipment	$1.47M
Long-Term Assets	$9.36M
Total Assets	$265.49M
Current Liabilities	$36.94M
Long-Term Debt	$29.82M
Long-Term Liabilities	$31.57M
Total Liabilities	$68.50M
Common Equity	$196.99M
Tangible Shareholders Equity	$193.12M
Shareholders Equity	$196.99M
Common Shares Outstanding	34.21M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-117.49M
Cash Flow from Investing Activities	$140.60M
Cash Flow from Financial Activities	$130.18M
Beginning Cash	$71.66M
End Cash	$224.95M
Increase/Decrease in Cash	$153.29M
Stock-Based Compensation	$19.83M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	6.93
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.13
Debt to Equity Ratio	0.15
Gross Margin	90.87%
Operating Margin	-820.53%
EBIT Margin	-820.53%
EBITDA Margin	-831.43%
Pre-Tax Profit Margin	-778.89%
Profit Margin	-778.89%
Free Cash Flow	$-119.00M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.07
Inventory Turnover	0.51
Receiveable Turnover	0.98
Days Sales in Receivables	370.59
Return on Equity	-68.99%
Return on Tangible Equity	-70.37%
Return on Assets	-51.19%
Return on Investments	-59.92%
Book Value Per Share	$5.76
Free Cash Flow per Share	$-4.05
Operating Cash Flow per Share	$-4.00

Data from Zacks Investment Research, Inc.